Page last updated: 2024-12-04

benzamidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzamidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benzamidine : A carboxamidine that is benzene carrying an amidino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2332
CHEMBL ID20936
CHEBI ID41033
SCHEMBL ID9207
MeSH IDM0100519
PubMed CID444655
CHEMBL ID79897
CHEBI ID187892
MeSH IDM0100519

Synonyms (86)

Synonym
smr000471900
MLS001066369
benzamidine (protonated)
bdbm50038002
nsc243704
benzenecarboximidamide
nsc-243704
AE-641/30119009
NCGC00015160-01
lopac-b-6506
BEN ,
LOPAC0_000203
phenylamidine
benzamidinium chloride
C01784
618-39-3
benzenecarboxamidine
benzamidine
CHEBI:41033 ,
1C5Z
1J14
1CE5
1V2V
1H4W
1C5P
1J16
1V2S
1BRA
1V2U
1V2J
1V2M
1J15
1V2L
1C5O
2AST
1F5K
1W80
1OSS
NCGC00162090-01
nsc 243704
einecs 210-546-3
ccris 2952
2J9N
64F5C29D-34E7-4815-B5F3-CC94EA3D2CAD
NCGC00015160-03
AKOS000201384
CHEMBL20936 ,
FT-0694841
STL163510
BBL012141
CCG-204298
benzimidamide
HMS2233B11
NCGC00015160-04
NCGC00015160-02
unii-kue3zy3j1f
kue3zy3j1f ,
AB01943
HMS3370L08
gtpl7566
AB00691669-14
SCHEMBL9207
DTXSID8045012
BS-3750
Q-100255
mfcd00042826
F1905-7123
NCGC00015160-05
Q4890748
125772-71-6
123920-06-9
.beta.-allo-2-octulopyranose, 2,7-anhydro-1,4,8-trideoxy-5-o-(phenylmethyl)-
SDCCGSBI-0050191.P002
NCGC00015160-07
AMY31187
benzamidine;benzimidamide
A852076
CS-0103011
SY096666
bdbm772
chembl79897
[amino(phenyl)methylidene]azanium
DB03127
benzamidinium
benzamidine(1+)
CHEBI:187892

Research Excerpts

Overview

Benzamidine is a reversible inhibitor that binds to plasmin's active site. Benzamidine was found to be a weak competitive inhibitor of the purified rat enzyme.

ExcerptReferenceRelevance
"Benzamidine is a reversible inhibitor that binds to plasmin's active site."( Multivalent Benzamidine Molecules for Plasmin Inhibition: Effect of Valency and Linker Length.
Alves, NJ; Nallan Chakravarthula, T; Zeng, Z, 2022
)
1.82
"Benzamidine was found to be a weak competitive inhibitor of the purified rat enzyme with Ki values of 30 and 10 mM at pH 8 and 9, respectively."( Purification of rat liver xanthine oxidase and xanthine dehydrogenase by affinity chromatography on benzamidine-sepharose.
McManaman, JL; Repine, JE; Shellman, V; Wright, RM, 1996
)
1.23

Bioavailability

ExcerptReferenceRelevance
" These data indicate that PA-III cell CM contains a 35 kDa proteinase capable of digesting the IGFBPs and thus increases the bioavailability of osteoblast-derived IGFs."( Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts.
Koutsilieris, M; Polychronakos, C,
)
0.13
" Hydrolysis of the IGFBOPs at the sites of PA-III cell-induced bone tumors account for an increased bioavailability of IGFs."( Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases.
Frenette, G; Govindan, MV; Koutsilieris, M; Lazure, C; Lehoux, JG; Polychronakos, C,
)
0.13
"In an effort to identify orally bioavailable factor Xa inhibitors, two isoxazolines libraries were prepared to scan for novel P1 ligands."( Discovery of 3-amino-4-chlorophenyl P1 as a novel and potent benzamidine mimic via solid-phase synthesis of an isoxazoline library.
Adams, JJ; Calhoun, WJ; Clark, CG; Knabb, RM; Lam, PY; Luettgen, JM; Wexler, RR, 2003
)
0.56
"N, N'-dihydroxybenzamdine represents a model compound for a new prodrug principle to improve the oral bioavailability of drugs containing amidine functions."( N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
Clement, B; Reeh, C; Wundt, J, 2007
)
0.34
"In general, drugs containing amidines suffer from poor oral bioavailability and are often converted into amidoxime prodrugs to overcome low uptake from the gastrointestinal tract."( Synthesis and biological evaluation of L-valine-amidoximeesters as double prodrugs of amidines.
Clement, B; Hungeling, H; Kotthaus, J; Reeh, C; Schade, D; Wein, S; Wolffram, S, 2011
)
0.37
"Ingestion of proteinase inhibitors leads to hyperproduction of digestive proteinases, limiting the bioavailability of essential amino acids for protein synthesis, which affects insect growth and development."( Enzymatic response of the eucalypt defoliator Thyrinteina arnobia (Stoll) (Lepidoptera: Geometridae) to a bis-benzamidine proteinase Inhibitor. i.
Guedes, RN; Lourenção, AL; Marinho-Prado, JS; Oliveira, JA; Oliveira, MG; Pallini, A, 2012
)
0.59

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve of glandular kallikrein in plasma paralleled that of purified kallikrein in both the immunoradiometric and the immunoenzymometric assays."( Excess antibody immunoassay for rat glandular kallikrein. Measurement of kallikrein complexed with inhibitors and in plasma.
Berg, T; Johansen, L; Nustad, K; Pierce, JV, 1984
)
0.27
" Linear dose-response curves were obtained and gave ED50 values (50% inhibition of fertilization) of 230 microM for BD, 27 microM for ABD, 35 nM for MUGB, and 13 nM for NPGB."( Inhibition of in-vitro fertilization of mouse gametes by proteinase inhibitors.
Beyler, SA; Zaneveld, LJ, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
serine protease inhibitorAny protease inhibitor that restricts the action of a serine protease.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
carboxamidineCompounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
carboxamidinium ionAny iminium ion resulting from the protonation of a carboxamidine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (59)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
arylsulfatase AHomo sapiens (human)Potency0.95281.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.06210.035520.977089.1251AID504332
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency50.11873.548119.542744.6684AID743266
flap endonuclease 1Homo sapiens (human)Potency8.43680.133725.412989.1251AID588795
gemininHomo sapiens (human)Potency3.77950.004611.374133.4983AID624296; AID624297
pyruvate kinase PKM isoform bHomo sapiens (human)Potency0.06312.511912.262825.1189AID954; AID958
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TRYPSINRattus rattus (black rat)Ki15,000.000015,000.000015,000.000015,000.0000AID977610
Chain H, Thrombin heavy chainHomo sapiens (human)Ki146.00000.210076.4417320.0000AID977610
Chain H, Thrombin heavy chainHomo sapiens (human)Ki146.00000.210076.4417320.0000AID977610
Chain A, PROTEIN (TRYPSIN)Bos taurus (cattle)Ki146.00000.210076.4417320.0000AID977610
Chain A, PROTEIN (TRYPSIN)Bos taurus (cattle)Ki146.00000.210076.4417320.0000AID977610
Chain A, PROTEIN (TRYPSIN)Bos taurus (cattle)Ki146.00000.210076.4417320.0000AID977610
Chain A, PROTEIN (TRYPSIN)Bos taurus (cattle)Ki146.00000.210076.4417320.0000AID977610
Chain B, PROTEIN (UROKINASE-TYPE PLASMINOGEN ACTIVATOR)Homo sapiens (human)Ki146.00000.210076.4417320.0000AID977610
Chain B, PROTEIN (UROKINASE-TYPE PLASMINOGEN ACTIVATOR)Homo sapiens (human)Ki146.00000.210076.4417320.0000AID977610
Chain B, PROTEIN (UROKINASE-TYPE PLASMINOGEN ACTIVATOR)Homo sapiens (human)Ki146.00000.210076.4417320.0000AID977610
Chain A, PROTEIN (TRYPSIN)Bos taurus (cattle)Ki18.400018.4000799.20001,580.0000AID977610
Chain U, UROKINASE-TYPE PLASMINOGEN ACTIVATORHomo sapiens (human)Ki180.00005.300092.6500180.0000AID977610
Chain A, UROKINASE-TYPE PLASMINOGEN ACTIVATORHomo sapiens (human)Ki180.00005.300092.6500180.0000AID977610
Chain A, UROKINASE-TYPE PLASMINOGEN ACTIVATORHomo sapiens (human)Ki180.00005.300092.6500180.0000AID977610
Chain A, TRYPSIN IVAHomo sapiens (human)Ki22.000022.000022.000022.0000AID977610
Chain A, trypsin II, anionicRattus norvegicus (Norway rat)Ki106.066732.2000106.0667143.0000AID977610
Chain A, Trypsin II, anionicRattus norvegicus (Norway rat)Ki106.066732.2000106.0667143.0000AID977610
Chain A, Trypsin II, anionicRattus norvegicus (Norway rat)Ki106.066732.2000106.0667143.0000AID977610
Chain T, Trypsin II, anionicRattus norvegicus (Norway rat)Ki106.066732.2000106.0667143.0000AID977610
Chain A, trypsinStreptomyces griseusKi16.400016.400016.400016.4000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain T, TrypsinBos taurus (cattle)Ki265.00001.2500227.3214566.0000AID977610
Chain A, PROTEIN (TRYPSIN)Bos taurus (cattle)Ki18.400018.4000799.20001,580.0000AID977610
ProthrombinHomo sapiens (human)Ki64.96000.00000.78469.0000AID1243412; AID211004; AID211033; AID211185
Prothrombin Bos taurus (cattle)Ki890.00000.00112.06948.3700AID213275
Coagulation factor XHomo sapiens (human)Ki0.30500.00000.47089.0000AID51847; AID52164
Coagulation factor XBos taurus (cattle)Ki160.00000.00700.62531.7000AID51339
Urokinase-type plasminogen activatorHomo sapiens (human)Ki180.00000.01702.62687.0000AID215815
Tissue-type plasminogen activatorHomo sapiens (human)Ki910.00000.01703.71968.6000AID210925
Cationic trypsinBos taurus (cattle)Ki18.26600.00001.07539.0000AID1721349; AID214849; AID214878; AID215059; AID215198; AID228433
AcrosinSus scrofa (pig)Ki4.00001.70002.87504.0000AID1133059
Coagulation factor VIIHomo sapiens (human)Ki240.00000.00021.55669.0000AID1201284
Suppressor of tumorigenicity 14 proteinHomo sapiens (human)Ki400.00000.00000.87113.3500AID1059677
ProthrombinHomo sapiens (human)IC50 (µMol)440.00000.00000.710710.0000AID1796917
ProthrombinHomo sapiens (human)Ki155.13850.00000.78469.0000AID1797113; AID1797179; AID1797227
Coagulation factor XHomo sapiens (human)Ki155.13850.00000.47089.0000AID1797113; AID1797179; AID1797227
PlasminogenHomo sapiens (human)Ki237.50000.01701.15604.4000AID1797227
Urokinase-type plasminogen activatorHomo sapiens (human)Ki200.92940.01702.62687.0000AID1797113; AID1797179; AID1797227; AID1797476
Tissue-type plasminogen activatorHomo sapiens (human)Ki247.07690.01703.71968.6000AID1797179; AID1797227; AID1797476
Cationic trypsinBos taurus (cattle)Ki196.05330.00001.07539.0000AID1797113; AID1797179; AID1797476
Serine protease hepsinHomo sapiens (human)Ki237.50000.00050.19170.8350AID1797227
Trypsin-1Homo sapiens (human)Ki237.50000.00001.76768.9000AID1797227
Tryptase beta-2Homo sapiens (human)Ki201.44440.00101.05323.7000AID1797179; AID1797227
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ProthrombinHomo sapiens (human)Kd405.00000.00000.01010.0387AID1243413; AID1243414
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldehyde oxidaseHomo sapiens (human)Kii1,620.00000.00700.65351.3000AID1807420
Aldehyde oxidaseHomo sapiens (human)Kis1,240.00001.30001.30001.3000AID1807414
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (118)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
proteolysisProthrombin Bos taurus (cattle)
acute-phase responseProthrombin Bos taurus (cattle)
positive regulation of blood coagulationProthrombin Bos taurus (cattle)
protein polymerizationProthrombin Bos taurus (cattle)
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
proteolysisCoagulation factor XBos taurus (cattle)
blood coagulationCoagulation factor XBos taurus (cattle)
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaTissue-type plasminogen activatorHomo sapiens (human)
proteolysisTissue-type plasminogen activatorHomo sapiens (human)
blood coagulationTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
protein modification processTissue-type plasminogen activatorHomo sapiens (human)
fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of proteolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
prevention of polyspermyTissue-type plasminogen activatorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionTissue-type plasminogen activatorHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTissue-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationTissue-type plasminogen activatorHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
lipid metabolic processAldehyde oxidaseHomo sapiens (human)
xenobiotic metabolic processAldehyde oxidaseHomo sapiens (human)
neural tube closureSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
proteolysisSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
protein catabolic processSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
keratinocyte differentiationSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
epithelial cell morphogenesis involved in placental branchingSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
proteolysisPlasminogenHomo sapiens (human)
blood coagulationPlasminogenHomo sapiens (human)
negative regulation of cell population proliferationPlasminogenHomo sapiens (human)
negative regulation of cell-substrate adhesionPlasminogenHomo sapiens (human)
extracellular matrix disassemblyPlasminogenHomo sapiens (human)
tissue regenerationPlasminogenHomo sapiens (human)
fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationPlasminogenHomo sapiens (human)
myoblast differentiationPlasminogenHomo sapiens (human)
muscle cell cellular homeostasisPlasminogenHomo sapiens (human)
tissue remodelingPlasminogenHomo sapiens (human)
biological process involved in interaction with symbiontPlasminogenHomo sapiens (human)
negative regulation of fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of fibrinolysisPlasminogenHomo sapiens (human)
trophoblast giant cell differentiationPlasminogenHomo sapiens (human)
labyrinthine layer blood vessel developmentPlasminogenHomo sapiens (human)
mononuclear cell migrationPlasminogenHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionPlasminogenHomo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherinPlasminogenHomo sapiens (human)
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaTissue-type plasminogen activatorHomo sapiens (human)
proteolysisTissue-type plasminogen activatorHomo sapiens (human)
blood coagulationTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
protein modification processTissue-type plasminogen activatorHomo sapiens (human)
fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of proteolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
prevention of polyspermyTissue-type plasminogen activatorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionTissue-type plasminogen activatorHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTissue-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationTissue-type plasminogen activatorHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
proteolysisSerine protease hepsinHomo sapiens (human)
regulation of cell shapeSerine protease hepsinHomo sapiens (human)
positive regulation of gene expressionSerine protease hepsinHomo sapiens (human)
negative regulation of epithelial to mesenchymal transitionSerine protease hepsinHomo sapiens (human)
positive regulation of plasminogen activationSerine protease hepsinHomo sapiens (human)
positive regulation of cell growthSerine protease hepsinHomo sapiens (human)
basement membrane disassemblySerine protease hepsinHomo sapiens (human)
negative regulation of apoptotic processSerine protease hepsinHomo sapiens (human)
positive regulation by host of viral transcriptionSerine protease hepsinHomo sapiens (human)
negative regulation of epithelial cell proliferationSerine protease hepsinHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundSerine protease hepsinHomo sapiens (human)
potassium ion transmembrane transportSerine protease hepsinHomo sapiens (human)
cochlea morphogenesisSerine protease hepsinHomo sapiens (human)
response to thyroid hormoneSerine protease hepsinHomo sapiens (human)
pilomotor reflexSerine protease hepsinHomo sapiens (human)
positive regulation of hepatocyte proliferationSerine protease hepsinHomo sapiens (human)
positive regulation of thyroid hormone generationSerine protease hepsinHomo sapiens (human)
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
proteolysisComplement C1s subcomponentHomo sapiens (human)
complement activation, classical pathwayComplement C1s subcomponentHomo sapiens (human)
innate immune responseComplement C1s subcomponentHomo sapiens (human)
proteolysisTryptase beta-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombin Bos taurus (cattle)
calcium ion bindingProthrombin Bos taurus (cattle)
protein bindingProthrombin Bos taurus (cattle)
fibrinogen bindingProthrombin Bos taurus (cattle)
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor XBos taurus (cattle)
calcium ion bindingCoagulation factor XBos taurus (cattle)
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase activityTissue-type plasminogen activatorHomo sapiens (human)
signaling receptor bindingTissue-type plasminogen activatorHomo sapiens (human)
protein bindingTissue-type plasminogen activatorHomo sapiens (human)
phosphoprotein bindingTissue-type plasminogen activatorHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
aldehyde oxidase activityAldehyde oxidaseHomo sapiens (human)
iron ion bindingAldehyde oxidaseHomo sapiens (human)
identical protein bindingAldehyde oxidaseHomo sapiens (human)
protein homodimerization activityAldehyde oxidaseHomo sapiens (human)
molybdopterin cofactor bindingAldehyde oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingAldehyde oxidaseHomo sapiens (human)
NAD bindingAldehyde oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingAldehyde oxidaseHomo sapiens (human)
FAD bindingAldehyde oxidaseHomo sapiens (human)
serine-type endopeptidase activitySuppressor of tumorigenicity 14 proteinHomo sapiens (human)
serine-type peptidase activitySuppressor of tumorigenicity 14 proteinHomo sapiens (human)
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
protease bindingPlasminogenHomo sapiens (human)
endopeptidase activityPlasminogenHomo sapiens (human)
serine-type endopeptidase activityPlasminogenHomo sapiens (human)
signaling receptor bindingPlasminogenHomo sapiens (human)
protein bindingPlasminogenHomo sapiens (human)
serine-type peptidase activityPlasminogenHomo sapiens (human)
enzyme bindingPlasminogenHomo sapiens (human)
kinase bindingPlasminogenHomo sapiens (human)
protein domain specific bindingPlasminogenHomo sapiens (human)
apolipoprotein bindingPlasminogenHomo sapiens (human)
protein-folding chaperone bindingPlasminogenHomo sapiens (human)
protein antigen bindingPlasminogenHomo sapiens (human)
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase activityTissue-type plasminogen activatorHomo sapiens (human)
signaling receptor bindingTissue-type plasminogen activatorHomo sapiens (human)
protein bindingTissue-type plasminogen activatorHomo sapiens (human)
phosphoprotein bindingTissue-type plasminogen activatorHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
serine-type endopeptidase activitySerine protease hepsinHomo sapiens (human)
protein bindingSerine protease hepsinHomo sapiens (human)
peptidase activitySerine protease hepsinHomo sapiens (human)
serine-type peptidase activitySerine protease hepsinHomo sapiens (human)
serine-type exopeptidase activitySerine protease hepsinHomo sapiens (human)
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
serine-type endopeptidase activityComplement C1s subcomponentHomo sapiens (human)
calcium ion bindingComplement C1s subcomponentHomo sapiens (human)
protein bindingComplement C1s subcomponentHomo sapiens (human)
identical protein bindingComplement C1s subcomponentHomo sapiens (human)
serine-type endopeptidase activityTryptase beta-2Homo sapiens (human)
protein bindingTryptase beta-2Homo sapiens (human)
serine-type peptidase activityTryptase beta-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
collagen-containing extracellular matrixTissue-type plasminogen activatorHomo sapiens (human)
extracellular regionTissue-type plasminogen activatorHomo sapiens (human)
cytoplasmTissue-type plasminogen activatorHomo sapiens (human)
cell surfaceTissue-type plasminogen activatorHomo sapiens (human)
secretory granuleTissue-type plasminogen activatorHomo sapiens (human)
apical part of cellTissue-type plasminogen activatorHomo sapiens (human)
extracellular exosomeTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexTissue-type plasminogen activatorHomo sapiens (human)
Schaffer collateral - CA1 synapseTissue-type plasminogen activatorHomo sapiens (human)
glutamatergic synapseTissue-type plasminogen activatorHomo sapiens (human)
extracellular spaceTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
cytosolAldehyde oxidaseHomo sapiens (human)
extracellular exosomeAldehyde oxidaseHomo sapiens (human)
extracellular spaceSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
external side of plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
basolateral plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
extracellular regionPlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
plasma membranePlasminogenHomo sapiens (human)
external side of plasma membranePlasminogenHomo sapiens (human)
cell surfacePlasminogenHomo sapiens (human)
platelet alpha granule lumenPlasminogenHomo sapiens (human)
collagen-containing extracellular matrixPlasminogenHomo sapiens (human)
extracellular exosomePlasminogenHomo sapiens (human)
blood microparticlePlasminogenHomo sapiens (human)
Schaffer collateral - CA1 synapsePlasminogenHomo sapiens (human)
glutamatergic synapsePlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
collagen-containing extracellular matrixTissue-type plasminogen activatorHomo sapiens (human)
extracellular regionTissue-type plasminogen activatorHomo sapiens (human)
cytoplasmTissue-type plasminogen activatorHomo sapiens (human)
cell surfaceTissue-type plasminogen activatorHomo sapiens (human)
secretory granuleTissue-type plasminogen activatorHomo sapiens (human)
apical part of cellTissue-type plasminogen activatorHomo sapiens (human)
extracellular exosomeTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexTissue-type plasminogen activatorHomo sapiens (human)
Schaffer collateral - CA1 synapseTissue-type plasminogen activatorHomo sapiens (human)
glutamatergic synapseTissue-type plasminogen activatorHomo sapiens (human)
extracellular spaceTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
nuclear membraneSerine protease hepsinHomo sapiens (human)
endoplasmic reticulum membraneSerine protease hepsinHomo sapiens (human)
plasma membraneSerine protease hepsinHomo sapiens (human)
cell-cell junctionSerine protease hepsinHomo sapiens (human)
cell surfaceSerine protease hepsinHomo sapiens (human)
membraneSerine protease hepsinHomo sapiens (human)
apical plasma membraneSerine protease hepsinHomo sapiens (human)
neuronal cell bodySerine protease hepsinHomo sapiens (human)
extracellular exosomeSerine protease hepsinHomo sapiens (human)
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
extracellular regionComplement C1s subcomponentHomo sapiens (human)
blood microparticleComplement C1s subcomponentHomo sapiens (human)
extracellular spaceComplement C1s subcomponentHomo sapiens (human)
collagen-containing extracellular matrixTryptase beta-2Homo sapiens (human)
extracellular spaceTryptase beta-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (96)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID304877Mean resident time in po dosed pig2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
AID213275Inhibitory activity against bovine thrombin expressed as dissociation constant1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
AID1807414Mixed type inhibition of human AOX assessed as inhibitor dissociation constant by measuring changes in slope of the double reciprocal plot using phenanthridine as substrate by Michaelis-Menten analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case.
AID1243414Binding affinity to thrombin (unknown origin) by displacement titration based isothermal titration colorimetry2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Fragment Binding Can Be Either More Enthalpy-Driven or Entropy-Driven: Crystal Structures and Residual Hydration Patterns Suggest Why.
AID1133063Selectivity for boar spermatozoa acrosin over thrombin (unknown origin)1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives.
AID1059677Inhibition of matriptase-SP1 (615 to 855) (unknown origin) expressed in Escherichia coli BL21(DE3) using Boc-Gln-Ala-Arg-7-amido-4-methyl coumarin hydrobromide as substrate by fluorescence assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.
AID215198Inhibitory Activity against bovine trypsin2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
GRID/CPCA: a new computational tool to design selective ligands.
AID1133059Reversible competitive inhibition of boar spermatozoa acrosin using BzArgOEt as substrate by Dixon plot analysis1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives.
AID215916Binding affinity against trypsin2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID1708451Inhibition of human thrombin using Tos-Gly-Pro-Arg-AMC.TFA substrate by fluorescence based kinetic enzyme inhibition assay based Dixon plot analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
How a Fragment Draws Attention to Selectivity Discriminating Features between the Related Proteases Trypsin and Thrombin.
AID1721350Competitive inhibition of bovine trypsin using Z-Arg-SBzl as substrate at pH 7.5 at 25 degC2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Synthesis of 2-guanidinyl pyridines and their trypsin inhibition and docking.
AID211033Binding affinity against human thrombin2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water.
AID1201284Inhibition of human soluble tissue factor/factor VIIa expressed in Origami B (DE3) using D-Ile-Pro-Arg-pNA as substrate after 30 mins by spectrophotometric analysis2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening.
AID1243412Binding affinity to thrombin (unknown origin)2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Fragment Binding Can Be Either More Enthalpy-Driven or Entropy-Driven: Crystal Structures and Residual Hydration Patterns Suggest Why.
AID51847Binding affinity was evaluated against Coagulation factor X1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
Solid-phase synthesis of N-substituted amidinophenoxy pyridines as factor XA inhibitors.
AID304874Tmax in po dosed pig2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
AID214878Binding affinity against bovine trypsin2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water.
AID239526In vitro inhibitory activity towards Coagulation factor X was determined using chromogenic substrate, MeO-COD-CHG-Gly-Arg-pNA2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Design, synthesis, and evaluation of oxyanion-hole selective inhibitor substituents for the S1 subsite of factor Xa.
AID304879Volume of distribution in po dosed pig2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
AID1133064Selectivity for boar spermatozoa acrosin over kallikrein (unknown origin)1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives.
AID214849Inhibitory activity against bovine trypsin expressed as dissociation constant1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
AID1807420Mixed type inhibition of human AOX assessed as inhibitor dissociation constant by measuring changes in intercept of the double reciprocal plot using phenanthridine as substrate by Michaelis-Menten analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case.
AID215815Inhibitory activity against human urokinase plasminogen activator expressed as dissociation constant1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
AID1708455Inhibition of human trypsin using Mes-D-Arg-Gly-Arg-AMC.2TFA substrate by fluorescence based kinetic enzyme inhibition assay based Dixon plot analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
How a Fragment Draws Attention to Selectivity Discriminating Features between the Related Proteases Trypsin and Thrombin.
AID304880Clearance in po dosed pig2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
AID1506675Binding affinity to trypsin (unknown origin) assessed as on rate constant
AID304878AUC in po dosed pig2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
AID234945Selectivity is the ratio of Ki's against inhibition of thrombin and trypsin1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Design and synthesis of potent and highly selective thrombin inhibitors.
AID213367log Kd (Binding affinity against specified protein) value of the compound2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID1133065Selectivity for boar spermatozoa acrosin over trypsin (unknown origin)1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives.
AID304881Oral bioavailability in pig2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
AID1721349Competitive inhibition of bovine beta trypsin using Bz-Arg-NH-Np as substrate at pH 7 at 30 degC2020Bioorganic & medicinal chemistry, 08-15, Volume: 28, Issue:16
Synthesis of 2-guanidinyl pyridines and their trypsin inhibition and docking.
AID215059In vitro binding affinity by measuring the inhibition of bovine trypsin1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Design and synthesis of potent and highly selective thrombin inhibitors.
AID1243413Binding affinity to thrombin (unknown origin) by direct isothermal titration colorimetry2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Fragment Binding Can Be Either More Enthalpy-Driven or Entropy-Driven: Crystal Structures and Residual Hydration Patterns Suggest Why.
AID211004In vitro binding affinity by measuring the inhibition of human thrombin1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
Design and synthesis of potent and highly selective thrombin inhibitors.
AID228433Inhibitory concentration against bovine trypsin2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors.
AID52164Inhibitory concentration against human Coagulation factor Xa (fXa)2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors.
AID211185Inhibitory Activity against human thrombin2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
GRID/CPCA: a new computational tool to design selective ligands.
AID51339Inhibitory activity against bovine coagulation factor X expressed as dissociation constant1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
AID1674224Inhibition of human lung tryptase using Tosyl-Gly-Pro-Arg-p-nitroanilide as substrate preincubated for 5 mins followed by substrate addition and measured after 15 mins2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Fragment Linking Strategies for Structure-Based Drug Design.
AID210925Inhibitory activity against human tissue-type plasminogen activator expressed as dissociation constant1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
AID304875Cmax in po dosed pig2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
AID304876Half life in po dosed pig2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
AID304873Plasma concentration in pig at 10 mg/kg, po2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1811Experimentally measured binding affinity data derived from PDB1999Proteins, Dec-01, Volume: 37, Issue:4
Non-Boltzmann thermodynamic integration (NBTI) for macromolecular systems: relative free energy of binding of trypsin to benzamidine and benzylamine.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1999Proteins, Dec-01, Volume: 37, Issue:4
Non-Boltzmann thermodynamic integration (NBTI) for macromolecular systems: relative free energy of binding of trypsin to benzamidine and benzylamine.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Chemistry & biology, Apr, Volume: 7, Issue:4
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
AID1811Experimentally measured binding affinity data derived from PDB2000Chemistry & biology, Apr, Volume: 7, Issue:4
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
AID1811Experimentally measured binding affinity data derived from PDB2002Journal of molecular biology, Feb-01, Volume: 315, Issue:5
Crystal structure reveals basis for the inhibitor resistance of human brain trypsin.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2002Journal of molecular biology, Feb-01, Volume: 315, Issue:5
Crystal structure reveals basis for the inhibitor resistance of human brain trypsin.
AID1811Experimentally measured binding affinity data derived from PDB2003Biochemistry, Aug-05, Volume: 42, Issue:30
Engineering the primary substrate specificity of Streptomyces griseus trypsin.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2003Biochemistry, Aug-05, Volume: 42, Issue:30
Engineering the primary substrate specificity of Streptomyces griseus trypsin.
AID1811Experimentally measured binding affinity data derived from PDB2004Journal of molecular biology, Jan-30, Volume: 335, Issue:5
Understanding protein-ligand interactions: the price of protein flexibility.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2004Journal of molecular biology, Jan-30, Volume: 335, Issue:5
Understanding protein-ligand interactions: the price of protein flexibility.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2003Journal of molecular biology, Jan-31, Volume: 325, Issue:5
Reconstructing the binding site of factor Xa in trypsin reveals ligand-induced structural plasticity.
AID1811Experimentally measured binding affinity data derived from PDB2003Journal of molecular biology, Jan-31, Volume: 325, Issue:5
Reconstructing the binding site of factor Xa in trypsin reveals ligand-induced structural plasticity.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Journal of molecular biology, Aug-11, Volume: 301, Issue:2
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
AID1811Experimentally measured binding affinity data derived from PDB2000Journal of molecular biology, Aug-11, Volume: 301, Issue:2
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
AID1811Experimentally measured binding affinity data derived from PDB1993Journal of molecular biology, Apr-05, Volume: 230, Issue:3
Relocating a negative charge in the binding pocket of trypsin.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1993Journal of molecular biology, Apr-05, Volume: 230, Issue:3
Relocating a negative charge in the binding pocket of trypsin.
AID1797179Enzyme Assay and Determination of the Inhibition Constants from Article 10.1016/S1074-5521(00)00104-6: \\Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.\\2000Chemistry & biology, Apr, Volume: 7, Issue:4
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
AID1796917Thrombin Assay from Article 10.1021/jm050850v: \\Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors.\\2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors.
AID1797113Enzyme Assay and Determination of the Inhibition Constants from Article 10.1006/jmbi.2001.4516: \\A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.\\2001Journal of molecular biology, Apr-13, Volume: 307, Issue:5
A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
AID1797227Enzyme Assay and Determination of the Inhibition Constants from Article 10.1016/j.jmb.2004.09.032: \\Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).\\2004Journal of molecular biology, Nov-19, Volume: 344, Issue:2
Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
AID1797476Determination of Inhibition Constants from Article 10.1006/jmbi.2000.3966: \\Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.\\2000Journal of molecular biology, Aug-11, Volume: 301, Issue:2
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
AID1799881Enzymatic Assay from Article 10.1021/bi00839a042: \\Nature of the active site of a subunit of the first component of human complement.\\1969Biochemistry, Nov, Volume: 8, Issue:11
Nature of the active site of a subunit of the first component of human complement.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (281)

TimeframeStudies, This Drug (%)All Drugs %
pre-199055 (19.57)18.7374
1990's62 (22.06)18.2507
2000's74 (26.33)29.6817
2010's74 (26.33)24.3611
2020's16 (5.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.51 (24.57)
Research Supply Index5.68 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index71.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.69%)5.53%
Trials0 (0.00%)5.53%
Reviews2 (0.69%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other287 (98.63%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]